Objectives: The antiphospholipid syndrome (APS) is an autoimmune disease associated with thrombotic and non-thrombotic neurologic manifestations. APS is classified as primary (PAPS) or secondary (SAPS) when it co-exists with another autoimmune disease. We aim to describe the spectrum of acute cerebrovascular disease among patients with APS, their differences between stroke subtypes, and long-term functional outcomes. Methods: Retrospective cohort study including adult (≥18 years) patients with APS followed in the stroke clinic of a tertiary-care reference center for autoimmune diseases in Mexico from 2009 to 2019. Results: We studied 120 cases; 99 (82.5%) women; median age 43 years (interquartile range 35–52); 63.3% with SAPS. Demographics, comorbidities, and antiphospholipid antibodies (aPL) positivity were similar between APS type and stroke subtypes. Amongst index events, we observed 84 (70%) acute ischemic strokes (AIS), 19 (15.8%) cerebral venous thromboses (CVT), 11 (9.2%) intracerebral hemorrhages (ICH), and six (5%) subarachnoid hemorrhages (SAH). Sixty-seven (55.8%) were known patients with APS; the median time from APS diagnosis to index stroke was 46 months (interquartile range 12–96); 64.7% of intracranial hemorrhages (ICH or SAH) occurred ≥4 years after APS was diagnosed (23.5% anticoagulation-related); 63.2% of CVT cases developed before APS was diagnosed or simultaneously. Recurrences occurred in 26 (22.8%) patients, AIS, in 18 (69.2%); intracranial hemorrhage, in eight (30.8%). Long-term functional outcomes were good (modified Rankin Scale ≤2) in 63.2% of cases, during follow-up, the all-cause mortality rate was 19.2%. Conclusion: We found no differences between stroke subtypes and APS types. aPL profiles were not associated with any of the acute cerebrovascular diseases described in this cohort. CVT may be an initial thrombotic manifestation of APS with low mortality and good long-term functional outcome.
16 September 2025 in International Journal of Stroke
Background: Stroke globally impacts mortality and disability. Compliance with international standards and evidence-based practices for acute stroke management would improve patient outcomes. Objectives: We aimed to present a descriptive analysis of the quality of acute stroke care across different countries using the Registry of Stroke Care Quality (RES-Q). Method: In a cross-sectional study, data from key quality indicators such as Emergency Medical Services (EMS) deployment rates, hospital arrival to imaging time (door-to-imaging: DIT), hospital arrival to thrombolysis time (door-to-needle: DNT), and Stroke Unit Care/Intensive Care Unit (SU/ICU) admission frequencies were examined. The analysis employed descriptive statistics and Spearman correlation tests. Results: Of 334,184 patients from 1130 hospitals in 70 countries, 218,832 patients (65.5%) from 47 countries were diagnosed with acute ischemic stroke after exclusions. The number of patients per country ranged from 226 to 62,080. International variability in care quality was observed: EMS (7–97%); SU/ICU (12–100%); and median DIT (7–41 min); and DNT (20–75 min). IVT rates varied markedly across countries, ranging from <1% to 52%. Higher patient volumes were positively correlated with SU/ICU admission and negatively with DIT and DNT (ρ = 0.10, –0.22, –0.42, respectively). Conclusion: This study demonstrates substantial international variation in the use of quality monitoring in clinical practice as well as in key indicators of acute ischemic stroke care, including intravenous thrombolysis rates and treatment timelines. The extent of variability highlights opportunities for benchmarking and targeted quality improvement efforts across diverse healthcare systems.
15 November 2026 in Annals of the Child Neurology Society
Background: Autoimmune encephalitis (AE) in children represents a group of immune‐mediated brain disorders with mild to severe neurological complications that are mostly recoverable with appropriate timely therapy. AE is complicated to diagnose and manage, particularly in Latin America, where access to diagnostic tests and treatments is limited. This study aimed to compare clinical outcomes in pediatric patients with AE who tested positive for autoantibodies versus those who tested negative. Methods: We conducted a retrospective cohort, secondary analysis of the multicenter study REAL LABIC, including data from multiple countries in Latin America. We divided patients with AE into two groups based on their autoimmune antibody status: those with positive antibodies (Ab+) and those with negative antibodies (Ab−). We compared presentation, treatment responses, and clinical outcomes between the two groups. Results: A total of 37 (59.7%) were Ab+, while 25 (40.3%) were Ab−. Neurological symptoms at admission were similar between groups, except for behavioral disturbances, which were more frequent in Ab+ patients (89% vs. 60%, p = 0.012) and required more aggressive treatment, including second‐line therapies, intensive care unit (ICU) admission, and mechanical ventilation. Conclusions: Children with antibody‐positive AE in Latin America had a more severe disease course and required more intensive therapeutic interventions than antibody‐negative patients. These findings underscore the importance of timely diagnosis and equitable access to advanced diagnostic and therapeutic resources in the region.